Crossmark

XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy

Published Online: 2021-10-09

Published Print: 2021-12

Authors

Li, Xuanzong http://orcid.org/0000-0001-5891-1569
Zou, Bing

Wang, Shijiang

Wang, Linlin

Yu, Jinming
License Information

Text and Data Mining valid from 2021-10-09

Version of Record valid from 2021-10-09
More Information

Article History

Received: 21 September 2021

Accepted: 28 September 2021

First Online: 9 October 2021

Declarations

:

: Since the study is based on public data, the informed consent and ethical proof are not required.

: All authors give their consent to publish this manuscript.

: The author declared no competing interests.

Document is current